Back

Effects of an Industrial Hemp-Based Nutraceutical on Post-Operative TPLO Pain

Nov 12, 2019

*NOTE: Enrollment is closed for this study*

Study Objective

The use of cannabinoid derivatives in the treatment of a variety of neurological disorders in humans has recently been explored, particularly in the treatment of chronic pain and epilepsy. Full spectrum cannabinoid rich industrial hemp-based nutraceuticals (HBN) below 0.3% THC have been shown to have no psychotropic effects and modest activity through non-cannabinoid receptor routes affecting the serotonergic, glycinergic and GABA neurotransmission pathways that may be able to diminish pain, as well as inflammation.

Some patients will receive a placebo and regular pain medication post surgery. The other patients will get the hemp-derived nutraceutical in addition to the regular pain medication.

Eligibility Requirements:

  • Dog undergoing TPLO surgery
  • Owner must sign consent form
  • Owner must agree to complete canine brief inventory of pain and Helsinki scale scores for their dog

Owner Incentive:

Owner is responsible for surgery and all costs associated. The study charges are covered by the Sponsor.

Contact:

Garrett Davis, DVM, DACVS
Jason Tarricone, DVM, Resident in Small Animal Surgery
Surgery Department

Red Bank Veterinary Hospital
197 Hance Ave, Tinton Falls, NJ 07724
(732) 747-3636

See All Clinical Studies